Finance

Should You Invest in Syntel, Inc. (SYNT)? A Look at the Insider Trends

Recent insider trends for Syntel, Inc. (NASDAQ:SYNT) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. SYNT’s insider trading patterns have some implications for where the stock might be headed.

Institutions own 35.92% of Syntel, Inc. (SYNT)’s shares. The total value of these holdings, in millions, is $701. Among active positions in the latest quarter, 66 holders increased their positions by a total of 4.78 million shares, 49 holders decreased the positions by a total of 1.58 million shares, and 31 holders held their positions. This works out to a net increase in ownership of 3.2 million shares, and suggests that institutions are feeling bullish about the stock.

Among new and sold out positions, 19 holders initiated new positions by a total of 2.16 million shares and 14 holders exited their positions by a total of 390622 shares. This nets out to an increase of 1.77 million shares and is a bullish sign for SYNT.

In the last three months, insiders executed a total of 9 trades. 9 were sells. Insider ownership decreased by a total of 3461 shares, which suggests that SYNT’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 54 buys and 11 sells, and ownership increased by a net of 478078 shares.



Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Syntel, Inc. (NASDAQ:SYNT)’s short interest is 3.57 million shares, or 9.14% of the float. This represents an increase of 15% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.

In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for SYNT. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that SYNT is a Strong buy, which implies that SYNT is expected to outperform the market based on prior trading patterns.

Conclusion




Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that Syntel, Inc. (NASDAQ:SYNT) is undervalued.

SYNT, Syntel, Inc., NASDAQ:SYNT

Are Investors Buying or Selling Ritter Pharmaceuticals, Inc. (RTTR), and What Should You Do?

Recent insider trends for Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) have caught the attention of investors. Insider data is useful because it can reveal what a company’s executives and largest shareholders feel about a stock. In this case, the data has some interesting things to say about how RTTR might perform in the future.

Institutions own 02.21% of Ritter Pharmaceuticals, Inc. (RTTR)’s shares. The total value of these holdings, in millions, is $0. Among active positions in the latest quarter, 5 holders increased their positions by a total of 47454 shares, 7 holders decreased the positions by a total of 1.03 million shares, and 5 holders held their positions. This works out to a net decrease in ownership of 984572 shares, and suggests that institutions are feeling bearish about the stock.

Among new and sold out positions, 3 holders initiated new positions by a total of 27294 shares and 4 holders exited their positions by a total of 931150 shares. This nets out to a decrease of 903856 shares and is another bearish sign for RTTR.

In the last three months, insiders executed a total of 4 trades. 4 of these were buys. Insider ownership increased by a total of 10.38 million shares, which suggests that RTTR’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 7 buys, and ownership increased by a net of 10.42 million shares.

Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR)’s short interest is 730500 shares, or 9.74% of the float. This represents an increase of 18% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.

In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for RTTR. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that RTTR is a sell, which implies that RTTR is expected to underperform the market based on prior trading patterns.

Conclusion

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) is overvalued.

Previous ArticleNext Article

Related Post

Why You Should Still Buy CARBO Ceramics (CRR) Stoc... CARBO Ceramics Inc. (NYSE:CRR) gained 5.91% in yesterday’s trading session, going up from its prior closing price of $6.94 to $7.35, and has now recor...
Reviewing the Insider Trends for Corbus Pharmaceut... Recent insider trends for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have caught the attention of investors. Insider activity is often a stro...
Scorpio Tankers (STNG) Is Driving on Undecided Tec... Scorpio Tankers Inc. (NYSE:STNG) fell by -3.99% in Monday’s trading session from $3.51 to $3.37. The price has fallen in 6 of the last 10 days and is ...
Finisar Corporation (FNSR): Watch Out For Technica... Finisar Corporation (NASDAQ:FNSR) fell by -3.77% in Monday’s trading session from $21.75 to $20.93. The price has been moving in both directions for t...
Are Investors Buying or Selling TherapeuticsMD, In... Recent insider trends for TherapeuticsMD, Inc. (NASDAQ:TXMD) have caught the attention of investors. Analysts monitor insider data to understand the s...